Cargando…

ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery

Deconvolution of targets and action mechanisms of anticancer compounds is fundamental in drug development. Here, we report on ProTargetMiner as a publicly available expandable proteome signature library of anticancer molecules in cancer cell lines. Based on 287 A549 adenocarcinoma proteomes affected...

Descripción completa

Detalles Bibliográficos
Autores principales: Saei, Amir Ata, Beusch, Christian Michel, Chernobrovkin, Alexey, Sabatier, Pierre, Zhang, Bo, Tokat, Ülkü Güler, Stergiou, Eleni, Gaetani, Massimiliano, Végvári, Ákos, Zubarev, Roman A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915695/
https://www.ncbi.nlm.nih.gov/pubmed/31844049
http://dx.doi.org/10.1038/s41467-019-13582-8
_version_ 1783480076222857216
author Saei, Amir Ata
Beusch, Christian Michel
Chernobrovkin, Alexey
Sabatier, Pierre
Zhang, Bo
Tokat, Ülkü Güler
Stergiou, Eleni
Gaetani, Massimiliano
Végvári, Ákos
Zubarev, Roman A.
author_facet Saei, Amir Ata
Beusch, Christian Michel
Chernobrovkin, Alexey
Sabatier, Pierre
Zhang, Bo
Tokat, Ülkü Güler
Stergiou, Eleni
Gaetani, Massimiliano
Végvári, Ákos
Zubarev, Roman A.
author_sort Saei, Amir Ata
collection PubMed
description Deconvolution of targets and action mechanisms of anticancer compounds is fundamental in drug development. Here, we report on ProTargetMiner as a publicly available expandable proteome signature library of anticancer molecules in cancer cell lines. Based on 287 A549 adenocarcinoma proteomes affected by 56 compounds, the main dataset contains 7,328 proteins and 1,307,859 refined protein-drug pairs. These proteomic signatures cluster by compound targets and action mechanisms. The targets and mechanistic proteins are deconvoluted by partial least square modeling, provided through the website http://protargetminer.genexplain.com. For 9 molecules representing the most diverse mechanisms and the common cancer cell lines MCF-7, RKO and A549, deep proteome datasets are obtained. Combining data from the three cell lines highlights common drug targets and cell-specific differences. The database can be easily extended and merged with new compound signatures. ProTargetMiner serves as a chemical proteomics resource for the cancer research community, and can become a valuable tool in drug discovery.
format Online
Article
Text
id pubmed-6915695
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-69156952019-12-18 ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery Saei, Amir Ata Beusch, Christian Michel Chernobrovkin, Alexey Sabatier, Pierre Zhang, Bo Tokat, Ülkü Güler Stergiou, Eleni Gaetani, Massimiliano Végvári, Ákos Zubarev, Roman A. Nat Commun Article Deconvolution of targets and action mechanisms of anticancer compounds is fundamental in drug development. Here, we report on ProTargetMiner as a publicly available expandable proteome signature library of anticancer molecules in cancer cell lines. Based on 287 A549 adenocarcinoma proteomes affected by 56 compounds, the main dataset contains 7,328 proteins and 1,307,859 refined protein-drug pairs. These proteomic signatures cluster by compound targets and action mechanisms. The targets and mechanistic proteins are deconvoluted by partial least square modeling, provided through the website http://protargetminer.genexplain.com. For 9 molecules representing the most diverse mechanisms and the common cancer cell lines MCF-7, RKO and A549, deep proteome datasets are obtained. Combining data from the three cell lines highlights common drug targets and cell-specific differences. The database can be easily extended and merged with new compound signatures. ProTargetMiner serves as a chemical proteomics resource for the cancer research community, and can become a valuable tool in drug discovery. Nature Publishing Group UK 2019-12-16 /pmc/articles/PMC6915695/ /pubmed/31844049 http://dx.doi.org/10.1038/s41467-019-13582-8 Text en © The Author(s) 2019 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Saei, Amir Ata
Beusch, Christian Michel
Chernobrovkin, Alexey
Sabatier, Pierre
Zhang, Bo
Tokat, Ülkü Güler
Stergiou, Eleni
Gaetani, Massimiliano
Végvári, Ákos
Zubarev, Roman A.
ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery
title ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery
title_full ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery
title_fullStr ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery
title_full_unstemmed ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery
title_short ProTargetMiner as a proteome signature library of anticancer molecules for functional discovery
title_sort protargetminer as a proteome signature library of anticancer molecules for functional discovery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6915695/
https://www.ncbi.nlm.nih.gov/pubmed/31844049
http://dx.doi.org/10.1038/s41467-019-13582-8
work_keys_str_mv AT saeiamirata protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery
AT beuschchristianmichel protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery
AT chernobrovkinalexey protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery
AT sabatierpierre protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery
AT zhangbo protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery
AT tokatulkuguler protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery
AT stergioueleni protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery
AT gaetanimassimiliano protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery
AT vegvariakos protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery
AT zubarevromana protargetminerasaproteomesignaturelibraryofanticancermoleculesforfunctionaldiscovery